Targeted therapies, such as monoclonal antibodies, are an important part of cancer drug development. Monoclonal antibodies may be used either unlabeled or conjugated with radioactive isotopes, chemotherapeutics, or toxins to create more potent therapeutic agents. Antibody-drug Conjugates or ADC are monoclonal antibodies (mAbs) attached to biologically active drugs, usually chemotherapeutic agents, by chemical linkers with covalent bonds.
With experience in chemistry along with biologics expertise, MabPlex provides full services for the development and manufacturing of antibody-drug conjugates. MabPlex is one of the leading companies in the world providing this technically challenging service from development to commercial production at one location.
MabPlex‘ services begin by using our state-of-the-art antibody development and production facilities to develop and produce your antibody of choice. Next, chemistry experts synthesize the linker of choice as well as the correct cytotoxin. Then MabPlex’ process development department develops and scales up conjugation process. Finally, the manufacturing team completes the entire production under the cGMP conditions.
MabPlex offers one stop integrated development services ranging from the development of antibodies, linkers, and cytotoxins to the production of efficacious ADC drugs. Additionally, we implement innovative linker technologies to ensure that cytotoxins effectively conjugate to the antibodies and that the cytotoxins are only released into the target cells. MabPlex is fully confident that the company’s first class service can significantly speed up any ADC drug development process. MabPlex effectively shortens the product life cycle from development to commercialization through the management of traceable batch records with our quality by design approach.
MabPlex, founded in 2013, is a specialized, global CRO/CMO service provider, offering one-stop biologics development and manufacturing solutions to customers with a services from cell line development and process development to GMP manufacturing.
The company’s technical expertise allows them to provide effective and high-quality solutions for monoclonal antibody therapeutics and antibody-drug conjugate (ADC) to the biopharmaceutical industry.
MabPlex USA, Inc.
2978 Scott Blvd
Santa Clara, CA 95054
Contact us for more information about sponsorship opportunities.
Last Editorial Review: February 17, 2017
Copyright © 2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
Topics to be Covered Introduction To Antibody Conjugates Overview Of Techniques In Quantitative Pharmacology No Such Thing As A Magic Bullet: The Hidden Challenges Of ADC Discovery And Development...